3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
3
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Prostatic Neoplasms
3
Leukemia
2
Waldenstrom Macroglobulinemia
1
Uveal Melanoma
1
Triple Negative Breast Neoplasms
1
Stomatitis
1
Neoplasms
1
Neoplasm Metastasis
1
Melanoma
1
Lung Neoplasms
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Head and Neck Neoplasms
1
Glioma
1
Glioblastoma
1
Epstein-Barr Virus Infections
1
Cytomegalovirus Infections
1
Carcinoma, Non-Small-Cell Lung
1
Astrocytoma
1
Adenocarcinoma
1
Interventions
Temozolomide
69
Bevacizumab
40
Radiotherapy
22
Magnetic Resonance Spectroscopy
20
Irinotecan
17
Specimen Handling
10
Carboplatin
10
Carmustine
9
X-Rays
7
Radiation
7
olaparib
6
Surgical Procedures, Operative
6
Phantoms, Imaging
6
Nuclear Medicine Department, Hospital
6
Nivolumab
6
Everolimus
6
Cyclophosphamide
6
Biopsy
6
trametinib
5
Thalidomide
5
Cisplatin
5
pembrolizumab
4
palbociclib
4
fluorodopa F 18
4
erdafitinib
4
dabrafenib
4
Lomustine
4
Etoposide
4
Drug Therapy
4
Doxorubicin
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Glioma
×
Valacyclovir
×
Clear all
NCT00589875
2024-04-03
BrTK02
Candel Therapeutics, Inc.
Phase 2
Completed
52 enrolled
10 charts